Search Results - "Khouri, Maria"

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial by Jabbour, Elias, Ravandi, Farhad, Kebriaei, Partow, Huang, Xuelin, Short, Nicholas J, Thomas, Deborah, Sasaki, Koji, Rytting, Michael, Jain, Nitin, Konopleva, Marina, Garcia-Manero, Guillermo, Champlin, Richard, Marin, David, Kadia, Tapan, Cortes, Jorge, Estrov, Zeev, Takahashi, Koichi, Patel, Yogin, Khouri, Maria R, Jacob, Jovitta, Garris, Rebecca, O'Brien, Susan, Kantarjian, Hagop

“…The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound…”
Get more information

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes by Alatrash, Gheath, Qiao, Na, Zhang, Mao, Zope, Madhushree, Perakis, Alexander A, Sukhumalchandra, Pariya, Philips, Anne V, Garber, Haven R, Kerros, Celine, St John, Lisa S, Khouri, Maria R, Khong, Hiep, Clise-Dwyer, Karen, Miller, Leonard P, Wolpe, Steve, Overwijk, Willem W, Molldrem, Jeffrey J, Ma, Qing, Shpall, Elizabeth J, Mittendorf, Elizabeth A

“…Inefficient homing of adoptively transferred cytotoxic T lymphocytes (CTLs) to tumors is a major limitation to the efficacy of adoptive cellular therapy (ACT)…”
Get full text

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation by Khouri, Maria R, Jabbour, Elias J, Gulbis, Alison M, Turturro, Francesco, Ledesma, Celina, Korbling, Martin, Samuels, Barry I, Ahmed, Sairah, Alousi, Amin M, Ciurea, Stefan O, Marin, David, Patel, Krina K, Popat, Uday R, Bueso-Ramos, Carlos E, Bassett, Roland L, Khouri, Issa F

“…Abstract In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor…”
Get full text

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage by Jabbour, Elias, Sasaki, Koji, Ravandi, Farhad, Huang, Xuelin, Short, Nicholas J., Khouri, Maria, Kebriaei, Partow, Burger, Jan, Khoury, Joseph, Jorgensen, Jeffrey, Jain, Nitin, Konopleva, Marina, Garcia‐Manero, Guillermo, Kadia, Tapan, Cortes, Jorge, Jacob, Jovitta, Montalbano, Kathryn, Garris, Rebecca, O’Brien, Susan, Kantarjian, Hagop M.

“…Background The outcomes of patients with relapsed or refractory (R‐R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have…”
Get full text

Mutational Landscape and Survival Outcomes of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Harboring Cohesin Complex Mutations by Khouri, Maria, Bindal, Poorva, Pearson, Laurie, Gillis-Smith, Andrew, Cerny, Jan, Ramanathan, Muthalagu, Gerber, Jonathon, Patel, Shyam

Get full text

AML-360 Mutational Landscape and Survival Outcomes of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Harboring Cohesin Complex Mutations by Khouri, Maria, Bindal, Poorva, Pearson, Laurie, Gillis-Smith, Andrew, Cerny, Jan, Ramanathan, Muthalagu, Gerber, Jonathon, Patel, Shyam

“…Cohesin mutations occur in 10%-20% of myeloid malignancies. Data about the clinical outcomes of patients with AML or MDS who harbor cohesin mutations, and…”
Get full text

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors by Sasaki, Koji, Jabbour, Elias, Issa, Ghayas C., Garcia-Manero, Guillermo, Kadia, Tapan M., Wierda, William G., Yilmaz, Musa, DiNardo, Courtney D., Skinner, Jeffrey, Khouri, Maria, Pemmaraju, Naveen, Nasnas, Patrice, Pierce, Sherry A., Cortes, Jorge E., Kantarjian, Hagop M.

“…▪ Background: The survival of patients with chronic myeloid leukemia (CML) in chronic phase (CP) is approaching that of general population particularly in…”
Get full text

Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis by Sasaki, Koji, Kantarjian, Hagop M., Morita, Kiyomi, Short, Nicholas J., Konopleva, Marina, Jain, Nitin, Ravandi, Farhad, Garcia‐Manero, Guillermo, Wang, Sa, Khoury, Joseph D., Jorgensen, Jeffrey L., Champlin, Richard E., Khouri, Issa F., Kebriaei, Partow, Schroeder, Heather M., Khouri, Maria, Garris, Rebecca, Takahashi, Koichi, O’Brien, Susan M., Jabbour, Elias J.

“…Background The outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper‐CVAD + ofatumumab (hyper‐CVAD +…”
Get full text

Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis by Sasaki, Koji, Jabbour, Elias J., Issa, Ghayas C., Naqvi, Kiran, Skinner, Jeffrey, Anderson, Kristin, Dellasala, Sara E, Yilmaz, Musa, Ferrajoli, Alessandra, Bose, Prithviraj, Thompson, Philip A., Alvarado, Yesid, Jain, Nitin, Garcia-Manero, Guillermo, Takahashi, Koichi, Burger, Jan A., Borthakur, Gautam, Pemmaraju, Naveen, Haddad, Fadi, Khouri, Maria R, Paul, Shilpa, Pierce, Sherry A., Cortes, Jorge E., Kantarjian, Hagop

“…Background: Low-dose dasatinib was shown to be safe and effective in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). There is…”
Get full text

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab by Sasaki, Koji, Kantarjian, Hagop M., Ravandi, Farhad, Short, Nicholas J., Kebriaei, Partow, Huang, Xuelin, Jain, Nitin, Konopleva, Marina, Garcia-Manero, Guillermo, Champlin, Richard E., Kadia, Tapan M., Takahashi, Koichi, Rafei, Hind, Wang, Sa A, Khoury, Joseph D., Jorgensen, Jeffrey L., Khouri, Maria, Jacob, Jovitta, Garris, Rebecca, O'Brien, Susan M., Jabbour, Elias

“…Background: The combination of low-intensity therapy (mini-hyper-CVD) with inotuzumab ozogamicin with or without sequential blinatumomab is effective in…”
Get full text

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial by Sasaki, Koji, Kantarjian, Hagop M., Ravandi, Farhad, Short, Nicholas J., Kebriaei, Partow, Huang, Xuelin, Jain, Nitin, Konopleva, Marina, Garcia-Manero, Guillermo, Champlin, Richard E., Kadia, Tapan M., Takahashi, Koichi, Daver, Naval, Rafei, Hind, Khoury, Joseph D., Jorgensen, Jeffrey L., Wang, Sa A, Khouri, Maria R, Jacob, Jovitta, Garris, Rebecca, O'Brien, Susan M., Jabbour, Elias

“…Background: The outcome of patients with relapsed-refractory (R-R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin and blinatumomab are…”
Get full text

Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor by Short, Nicholas J., Kantarjian, Hagop M., Sasaki, Koji, Ravandi, Farhad, Ko, Heidi, Cameron Yin, C., Garcia‐Manero, Guillermo, Cortes, Jorge E., Garris, Rebecca, O'Brien, Susan M., Patel, Keyur, Khouri, Maria, Thomas, Deborah, Jain, Nitin, Kadia, Tapan M., Daver, Naval G., Benton, Christopher B., Issa, Ghayas C., Konopleva, Marina, Jabbour, Elias

“…In patients with Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI),…”
Get full text

Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia by Aboudalle, Iman, Kantarjian, Hagop M., Short, Nicholas J, Ravandi, Farhad, Sasaki, Koji, Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo, Cortes, Jorge E., Benton, Christopher B., Issa, Ghayas C., Khouri, Maria, Nasnas, Patrice, O'Brien, Susan M., Jabbour, Elias J.

“…Background: Relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL) is an aggressive malignant disease with poor long-term outcomes…”
Get full text

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis by Morita, Kiyomi, Sasaki, Koji, Richard-Carpentier, Guillaume, Konopleva, Marina, Huang, Xuelin, Short, Nicholas J., Jain, Nitin, Ravandi, Farhad, Dabaja, Bouthaina S., Daver, Naval, Kadia, Tapan M., Alvarado, Yesid, DiNardo, Courtney D., Issa, Ghayas C., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Verstovsek, Srdan, Wang, Sa A, Khoury, Joseph D., Jorgensen, Jeffrey L., Champlin, Richard E., Khouri, Issa F., Kebriaei, Partow, Schroeder, Heather M., Khouri, Maria, Takahashi, Koichi, O'Brien, Susan M., Kantarjian, Hagop M., Jabbour, Elias

“…Introduction: Outcome of patients (pts) with CD20-positive B-cell acute lymphoblastic leukemia (B-ALL) has significantly improved with hyper-CVAD (HCVAD) in…”
Get full text

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse by Rafei, Hind, Kantarjian, Hagop M., Sasaki, Koji, Short, Nicholas J., Ravandi, Farhad, Huang, Xuelin, Khoury, Joseph D., Wang, Sa A, Jorgensen, Jeffrey L., Khouri, Issa F., Kebriaei, Partow, Jain, Nitin, Dabaja, Bouthaina S., Alvarado, Yesid, Kadia, Tapan M., Paul, Shilpa, Chew, Serena, Garcia-Manero, Guillermo, Burger, Jan A., DiNardo, Courtney D., Daver, Naval, Montalban-Bravo, Guillermo, Yilmaz, Musa, Ohanian, Maro, Khouri, Maria, Thompson, Philip A., Jacob, Jovitta, Rostykus, Meagan, Garris, Rebecca, Konopleva, Marina, O'Brien, Susan M., Jabbour, Elias

“…Background: The combination of low intensity therapy with InO improved outcome compared to intensive chemotherapy and to single agent InO in Salvage 1. The…”
Get full text

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial by Jabbour, Elias, Richard-Carpentier, Guillaume, Sasaki, Yuya, Konopleva, Marina, Patel, Keyur, Roberts, Kathryn, Gu, Zhaohui, Wang, Feng, Huang, Xuelin, Sasaki, Koji, Short, Nicholas J, Jain, Nitin, Ravandi, Farhad, Daver, Naval G, Kadia, Tapan M, Alvarado, Yesid, DiNardo, Courtney D, Issa, Ghayas C, Pemmaraju, Naveen, Garcia-Manero, Guillermo, Verstovsek, Srdan, Wang, Sa, Khoury, Joseph D, Jorgensen, Jeffrey, Champlin, Richard, Khouri, Issa, Kebriaei, Partow, Schroeder, Heather, Khouri, Maria, Mullighan, Charles G, Takahashi, Koichi, O'Brien, Susan M, Kantarjian, Hagop

“…The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia. Ofatumumab is an anti-CD20…”
Get full text

Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma by Short, Nicholas J., Kantarjian, Hagop M., Ko, Heidi, Khoury, Joseph D., Ravandi, Farhad, Thomas, Deborah A., Garcia‐Manero, Guillermo, Khouri, Maria, Cortes, Jorge E., Wierda, William G., Verstovsek, Srdan, Estrov, Zeev, Ferrajoli, Alessandra, Thompson, Philip A., Pierce, Sherry, O'Brien, Susan M., Jabbour, Elias

Get full text

Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) by Sasaki, Koji, Jabbour, Elias J., Khouri, Maria, Thomas, Deborah A, Garcia-Manero, Guillermo, Ravandi, Farhad, Borthakur, Gautam, Short, Nicholas J, Issa, Ghayas C., Kadia, Tapan, Jones, Emily, Garris, Rebecca, Cortes, Jorge E., O'Brien, Susan M., Kantarjian, Hagop M.

“…▪ Background: Liposomal vincristine is designed to reduce neurotoxicity and increase dose intensity delivery, and has been approved as salvage therapy for…”
Get full text

Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia by Assi, Rita, Kantarjian, Hagop M., Short, Nicholas J, Daver, Naval, Takahashi, Koichi, Garcia-Manero, Guillermo, DiNardo, Courtney D., Khouri, Maria, Burger, Jan A., Cortes, Jorge E., Jain, Nitin, Wierda, William G, Chamoun, Salim, Konopleva, Marina, Jabbour, Elias J.

“…Background: The treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been revolutionized with the introduction of…”
Get full text

Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) by Jabbour, Elias J., Sasaki, Koji, Ravandi, Farhad, Short, Nicholas J, Garcia-Manero, Guillermo, Daver, Naval G., Kadia, Tapan M., Konopleva, Marina Y., Jain, Nitin, Issa, Ghayas C., Estrov, Zeev E., Garris, Rebecca E., Khouri, Maria, Nasnas, Patrice, Pemmaraju, Naveen, Cortes, Jorge E., O'Brien, Susan M., Kantarjian, Hagop M.

“…Background: Cigarette smoking impairs response and outcome in pts with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell-lung cancer are…”
Get full text